Triangle Securities Wealth Management Sells 89 Shares of Amgen Inc. (NASDAQ:AMGN)

Triangle Securities Wealth Management cut its stake in Amgen Inc. (NASDAQ:AMGN) by 1.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,783 shares of the medical research company’s stock after selling 89 shares during the period. Triangle Securities Wealth Management’s holdings in Amgen were worth $1,868,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Birch Capital Management LLC grew its holdings in Amgen by 3.4% during the 2nd quarter. Birch Capital Management LLC now owns 21,721 shares of the medical research company’s stock worth $5,295,000 after acquiring an additional 708 shares in the last quarter. Silvercrest Asset Management Group LLC grew its holdings in Amgen by 1.0% during the 2nd quarter. Silvercrest Asset Management Group LLC now owns 364,468 shares of the medical research company’s stock worth $88,840,000 after acquiring an additional 3,546 shares in the last quarter. Arlington Financial Advisors LLC grew its holdings in Amgen by 8.3% during the 2nd quarter. Arlington Financial Advisors LLC now owns 25,724 shares of the medical research company’s stock worth $6,270,000 after acquiring an additional 1,962 shares in the last quarter. Mather Group LLC. grew its holdings in Amgen by 25.4% during the 2nd quarter. Mather Group LLC. now owns 5,591 shares of the medical research company’s stock worth $1,363,000 after acquiring an additional 1,134 shares in the last quarter. Finally, Calamos Advisors LLC grew its holdings in Amgen by 29.4% during the 2nd quarter. Calamos Advisors LLC now owns 77,154 shares of the medical research company’s stock worth $18,806,000 after acquiring an additional 17,549 shares in the last quarter. Hedge funds and other institutional investors own 74.95% of the company’s stock.

Shares of Amgen stock opened at $203.97 on Thursday. The firm has a market capitalization of $114.89 billion, a P/E ratio of 21.01, a PEG ratio of 1.47 and a beta of 0.61. The company has a quick ratio of 1.36, a current ratio of 1.64 and a debt-to-equity ratio of 4.05. The company has a 50 day moving average price of $209.99 and a 200 day moving average price of $227.76. Amgen Inc. has a 52 week low of $200.47 and a 52 week high of $276.69.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, November 2nd. The medical research company reported $4.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.22 by $0.45. Amgen had a net margin of 21.77% and a return on equity of 108.67%. During the same quarter last year, the firm posted $4.37 earnings per share. As a group, research analysts anticipate that Amgen Inc. will post 16.83 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 8th. Shareholders of record on Tuesday, November 16th will be given a dividend of $1.76 per share. This represents a $7.04 dividend on an annualized basis and a yield of 3.45%. The ex-dividend date is Monday, November 15th. Amgen’s dividend payout ratio is presently 72.50%.

Several research analysts have issued reports on AMGN shares. Barclays dropped their target price on shares of Amgen from $230.00 to $228.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 3rd. SVB Leerink decreased their price target on shares of Amgen from $234.00 to $216.00 and set a “market perform” rating for the company in a research report on Wednesday, November 3rd. Oppenheimer decreased their price target on shares of Amgen from $277.00 to $272.00 and set an “outperform” rating for the company in a research report on Monday, November 1st. Morgan Stanley decreased their price target on shares of Amgen from $251.00 to $235.00 and set an “equal weight” rating for the company in a research report on Tuesday, October 12th. Finally, BMO Capital Markets initiated coverage on shares of Amgen in a research report on Thursday, November 18th. They set a “market perform” rating and a $228.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Amgen has a consensus rating of “Hold” and a consensus target price of $235.50.

Amgen Profile

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA.

Read More: Dividend Achievers

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.